logo-loader
Silence Therapeutics PLC

Silence Therapeutics - Proactive One2One Investor Forum May 2019

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), presents at the Proactive Investors One2One Investor Forum in London May 2019.

For more information visit www.silence-therapeutics.com

Quick facts: Silence Therapeutics PLC

Price: £2.06

Market: AIM
Market Cap: £160.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics hails 'transformational' deal with US firm Mallinckrodt

Silence Therapeutics PLC's (LON:SLN) David Solomon discusses the partnership they've struck with US biopharmaceutical firm Mallinckrodt PLC (NYSE: MNK) to develop and commercialise gene silencing treatments for serious diseases. Mallinckrodt will obtain an exclusive worldwide license to...

on 22/7/19

RNS

Additional Listing

2 days, 1 hour ago

Additional Listing

3 days, 20 hours ago

Notice of Results and R&D day

1 week, 1 day ago

Additional Listing

1 week, 3 days ago

Additional Listing

2 weeks, 1 day ago

Additional Listing

2 weeks, 2 days ago

Additional Listing

2 weeks, 3 days ago

2 min read